Cit­ing patent in­fringe­ment, Lipocine sues Clarus; Sang­amo, DBV un­veil share of­fer­ings

→ Meta­bol­ic and en­docrine dis­or­der-fo­cused Lipocine $LPCN on Wednes­day said it was su­ing Clarus Ther­a­peu­tics for its re­cent­ly ap­proved oral testos­terone re­place­ment ther­a­py, Jaten­zo, al­leg­ing the lat­ter has in­fringed on 6 its US patents. Clarus shot back, say­ing “When the facts are brought be­fore the court, we are con­fi­dent that Lipocine’s as­ser­tions will be found to be with­out mer­it.”

→ Rid­ing the wave of its promis­ing — but ear­ly stage — snap­shot of its Pfiz­er $PFE-part­nered he­mo­phil­ia A gene ther­a­py, Sang­amo Ther­a­peu­tics $SG­MO on Wednes­day said it was of­fer­ing up more shares to raise funds in a pub­lic of­fer­ing — the size of the of­fer­ing and price per share will be re­vealed lat­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.